Early Diagnosis of Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (30 March 2022) | Viewed by 30482
Special Issue Editors
Interests: prostate cancer; biomarkers; diagnosis; patient stratification; molecular pathology; genomics; personalised medicine
Special Issue Information
Dear Colleagues,
The early diagnosis of cancer, before it has metastasised, is key to more effective—and often curative—treatment. For example, more than 90% of women diagnosed with breast cancer at the earliest stage survive their disease for at least 5 years compared to around 15% for women diagnosed with the most advanced stage of disease.
Making improvements in early cancer diagnosis covers a wide range of scientific disciplines, including fundamental research that aims to identify premalignant drivers of tumourigenesis or markers of early disease, translational studies that find ways to apply that research to the disease, and research into implementing advances in early diagnosis into the clinical pathway.
Underpinning all early diagnosis research is a clear definition of the clinically unmet need and an understanding of the current blockages in the diagnostic pathway and these will vary with different cancer types. Hence, while we may want to diagnose all pancreatic cancers, we may only want to diagnose the more aggressive prostate cancers that are more likely to be life limiting.
This Special Issue will highlight state-of-the-art research in improving the early diagnosis of cancers towards advancing the clinical impact of existing scientific knowledge.
Dr. Hayley C. Whitaker
Dr. Kelly Coffey
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- imaging
- biomarker
- genetics
- multidisciplinary
- translational research
- fluidics
- artificial intelligence
- survival
- treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.